Two performers identified in Ebola drugs trial
In what looks like a major landmark discovery in the treatment of Ebola, the World Health Organisation has said that two out of the four drugs being tested are more effective in treating the scourge that has continued to ravaging some parts of Africa.
The co-sponsors of the Ebola therapeutics trial in the Democratic Republic of the Congo (DRC) announced advances that will bring patients a better chance of survival.
They said that two out of the four drugs being tested are more effective in treating Ebola. Moving forward, these are the only drugs that future patients will be treated with.
This WHO initiative is the first-ever multi-drug randomized control trial aimed at evaluating the safety and efficacy of four drugs used for treatment of Ebola patients. Initially developed as a multi-outbreak, multi-country study, PALM, “Together save lives”, was launched in November 2018.
Read Also : 54gene secures $15 million Series A funding round to scale up
“It is part of the emergency response in DRC, in collaboration with a broad alliance of partners, including the DRC’s National Institute for Biomedical Research (INRB), Ministry of Health, National Institute of Allergy and Infectious Diseases (NIAID), which is part of the United States’ National Institutes of Health, Alliance for International Medical Action (ALIMA), Médecins Sans Frontières (MSF), the International Medical Corps (IMC), and other organizations”, WHO said.
In addition to researching the best treatments for Ebola, other efforts by team members and partners in the field are also critical in impacting survival rates.
Teams of epidemiologists and community members work with communities to identify cases and provide care as quickly as possible. The teams ensure contacts are vaccinated against the disease and that their health is monitored for three weeks.
Read Also: COVID-19: Ecobank group says it contributes about US$3 million across its Africa footprint
The organisation said that active case finding, contact tracing, and community acceptance of these teams are vital to ending the outbreak.
WHO is committed to continuing to work closely with the ministries of health of DRC and neighboring countries, and other international partners to ensure the outbreak response remains robust and well-coordinated.
“We will continue to conduct rigorous research and incorporate findings into the Ebola outbreak response through a variety of prevention and control strategies”, WHO said.
Two performers identified in Ebola drugs trial
